Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2007 1
2009 1
2015 2
2019 1
2020 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study.
Fernández de Larrea-Baz N, Pérez-Gómez B, Guerrero-Zotano Á, Casas AM, Bermejo B, Baena-Cañada JM, Antolin S, Sánchez-Rovira P, Ramos Vázquez M, Garcia-Sáenz JÁ, Antón A, Muñoz M, de Juan A, Jara C, Chacón JI, Arcusa A, Gil-Gil M, Adrover E, Oltra A, Brunet J, González S, Bezares S, Lope V, Martín M, Pollán M. Fernández de Larrea-Baz N, et al. Among authors: oltra a. Sci Rep. 2020 May 8;10(1):7741. doi: 10.1038/s41598-020-63637-w. Sci Rep. 2020. PMID: 32385335 Free PMC article.
Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors-Health-EpiGEICAM Study.
Lope V, Guerrero-Zotano A, Ruiz-Moreno E, Bermejo B, Antolín S, Montaño Á, Baena-Cañada JM, Ramos Vázquez M, Fernández de Larrea-Baz N, Chacón JI, García-Sáenz JA, Olier C, Muñoz M, Antón A, Sánchez Rovira P, Arcusa Lanza A, González S, Oltra A, Brunet J, Gavilá Gregori J, Martínez MT, Calvo L, Rosell L, Bezares S, Pastor-Barriuso R, Pérez-Gómez B, Martín M, Pollán M. Lope V, et al. Among authors: oltra a. Cancers (Basel). 2022 Sep 27;14(19):4705. doi: 10.3390/cancers14194705. Cancers (Basel). 2022. PMID: 36230628 Free PMC article.
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Bachelot T, et al. Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061. Ann Oncol. 2019. PMID: 30796821 Free article. Clinical Trial.
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).
Manso L, Hernando C, Galán M, Oliveira M, Cabrera MA, Bratos R, Rodríguez CA, Ruiz-Borrego M, Blanch S, Llombart-Cussac A, Delgado-Mingorance JI, Álvarez-Busto I, Gallegos I, González-Cortijo L, Morales S, Aguirre E, Hernando BA, Ballesteros A, Alés-Martínez JE, Reboredo C, Oltra A, González-Cao M, Santisteban M, Malón D, Echeverría I, García-Garre E, Vega E, Servitja S, Andrés R, Robles CE, López R, Galve E, Echarri MJ, Legeren M, Moreno F. Manso L, et al. Among authors: oltra a. Breast. 2020 Dec;54:286-292. doi: 10.1016/j.breast.2020.11.005. Epub 2020 Nov 13. Breast. 2020. PMID: 33242755 Free PMC article.
Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.
Garcia-Alfonso P, Chaves M, Muñoz A, Salud A, García-Gonzalez M, Grávalos C, Massuti B, González-Flores E, Queralt B, López-Ladrón A, Losa F, Gómez MJ, Oltra A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Garcia-Alfonso P, et al. Among authors: oltra a. BMC Cancer. 2015 Apr 29;15:327. doi: 10.1186/s12885-015-1293-y. BMC Cancer. 2015. PMID: 25925749 Free PMC article. Clinical Trial.
Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study.
Castelló A, Martín M, Ruiz A, Casas AM, Baena-Cañada JM, Lope V, Antolín S, Sánchez P, Ramos M, Antón A, Muñoz M, Bermejo B, De Juan-Ferré A, Jara C, Chacón JI, Jimeno MA, Rosado P, Díaz E, Guillem V, Lluch A, Carrasco E, Pérez-Gómez B, Vioque J, Pollán M; EpiGEICAM Researchers. Castelló A, et al. PLoS One. 2015 May 15;10(5):e0126096. doi: 10.1371/journal.pone.0126096. eCollection 2015. PLoS One. 2015. PMID: 25978407 Free PMC article.
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study.
Morales S, Lorenzo A, Ramos M, Ballesteros P, Méndez M, Almanza C, Castellanos J, Moreno-Nogueira JA, Casal J, Lizón J, Oltra A, Frau A, Machengs I, Galán A, Belón J, Llorca C. Morales S, et al. Among authors: oltra a. Cancer Chemother Pharmacol. 2004 Jan;53(1):75-81. doi: 10.1007/s00280-003-0690-0. Epub 2003 Oct 14. Cancer Chemother Pharmacol. 2004. PMID: 14557896 Clinical Trial.